Malaria vaccines market
Malaria Vaccines Market, by Agent (Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species), by Vaccine Type (Pre-Erythrocytic, Erythrocytic and Multi-antigen), by Distribution Channel (Public and Private) and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
- Jun 2022
- CMI37
- 166 Pages
- Excel & Pdf
- Pharmaceutical
Malaria vaccines are therapeutics that offer protection against mosquito-borne infectious disease called malaria. Malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. Individuals who get malaria are typically very sick with high fevers, shaking chills, and flu-like illness. Although malaria can be a deadly disease, illness and death from malaria can usually be prevented.
Global Malaria Vaccines Market is estimated to be valued at US$ 41.08 million in 2022 and is expected to exhibit a CAGR of 29.6% during the forecast period (2022-2030).
Figure 1.Global Malaria Vaccines Market Share (%) in Terms of Value, By Agent, 2022
Increasing government initiatives for prevention of malaria are expected to drive market growth during the forecast period.
Increasing government initiatives for prevention of malaria are expected to drive the global malaria vaccines market growth over the forecast period. For instance, in October 2021, the World Health Organization (WHO) recommended widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission. The recommendation was based on results from an ongoing pilot programme in Ghana, Kenya and Malawi that has reached more than 900 000 children since 2019.
Malaria Vaccines Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2021 | Market Size in 2022: | US$ 41.08 Mn |
Historical Data for: | 2017-2020 | Forecast Period: | 2022 to 2030 |
Forecast Period 2022 to 2030 CAGR: | 29.6% | 2030 Value Projection: | US$ 357.95 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
GlaxoSmithKline, Nobelpharma, Sanaria, CellFree Sciences, VLP Therapeutics LLC, Sumaya Biotech, BioNTech, and Precigen, Inc |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Figure 2.Global Malaria Vaccines Market Share (%), By Vaccine Type, 2022
Rising inorganic strategies by key players for development of malaria vaccine are expected to drive the market growth during the forecast period
Rising inorganic strategies such as agreements by key players for development of malaria vaccine are expected to drive global malaria vaccines market growth during the forecast period. For instance, October 2021, Sanaria Inc., a biotechnology company and Seattle Children’s Research Institute, the US’s best children’s hospitals, announced the signing of an agreement to collaborate on development and commercialization of next generation PfSPZ vaccines attenuated by genetic engineering. Sanaria PfSPZ Vaccine and Sanaria PfSPZ-CVac vaccine have shown 100% protective efficacy against controlled human malaria infection with highly variant Pf parasites and importantly, protection against Pf infection in multiple trials in Africa
Global Malaria Vaccines Market– Impact of Coronavirus (COVID-19) Pandemic
The coronavirus or COVID-19 outbreak started from Wuhan, China in 2019 and has spread across all the continents of the world, affecting various industries globally. Economy in countries all over the world such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others has been disrupted due to lockdowns implemented by governments to combat spread of coronavirus since 2020. Furthermore, the COVID-19 pandemic is affecting malaria control efforts. For instance, according to data published in BioMed Central Ltd, a U. K.-based, for-profit scientific open access publisher in April 2020, due to the COVID-19 pandemic, a consortium established for testing malaria vaccines had joined to combat COVID-19, thus possibly decreasing their resources for malaria vaccines. External funds might be diverted for the same reason. Avoidance of health care facilities means a decrease of participants.
Global Malaria Vaccines Market: Restraint
The major factors that hinder growth of the global malaria vaccines market include barriers to developing a malaria vaccine. For instance, according to data published by Centers for Disease Control and Prevention in October 2021, development of a malaria vaccine has faced several obstacles: the lack of a traditional market, few developers, and the technical complexity of developing any vaccine against a parasite. Malaria parasites have a complex life cycle, and there is poor understanding of the complex immune response to malaria infection. Malaria parasites are also genetically complex, producing thousands of potential antigens. Unlike the diseases for which we currently have effective vaccines, exposure to malaria parasites does not confer lifelong protection.
Key Players
Key players operating in the market include GlaxoSmithKline, Nobelpharma, Sanaria, CellFree Sciences, VLP Therapeutics LLC, Sumaya Biotech, BioNTech, and Precigen, Inc.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Agent
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Distribution Channels
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Regulatory Scenario
- Market Trends
- Pipeline Analysis
- Key Developments
- Epidemiology
- PEST Analysis
- Collaboration and Acquisition
- Porters Analysis
- Vaccine Developmental Cycle
- Market Dynamics
- Global Malaria Vaccines Market – Impact of Coronavirus (COVID-19) Pandemic
- Economic Impact
- Impact on Demand and Supply
- COVID-19 Impact Assessments
- Global Malaria Vaccines Market, By Agent, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 – 2030
- Segment Trends
- Plasmodium Falciparum
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Plasmodium Vivax
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Anopheles Species
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Introduction
- Global Malaria Vaccines Market, By Vaccine Type, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 – 2030
- Segment Trends
- Pre-Erythrocytic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Erythrocytic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Multi-antigen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Introduction
- Global Malaria Vaccines Market, By Distribution Channel, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 – 2030
- Segment Trends
- Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Introduction
- Global Malaria Vaccines Market, By Region, 2017-2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2018–2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Agent, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017-2030,(US$ Mn)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Nobelpharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanaria
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CellFree Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- VLP Therapeutics LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sumaya Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- BioNTech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Precigen, Inc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline
- Section
- Research Methodology
- About us
*Browse 28 market data tables and 32 figures on "Global Malaria Vaccines Market” - Forecast to 2030
Detailed Segmentation:
- Global Malaria vaccine Market, By Agent :
- Plasmodium Falciparum
- Plasmodium Vivax
- Anopheles Species
- Global Malaria vaccine Market, By Vaccine Type :
- Pre-Erythrocytic
- Erythrocytic
- Multi-antigen
- Global Malaria vaccine Market, By Distribution Channel :
- Public
- Private
- Global Malaria vaccine Market, By Region:
- North America
- By Agent
- Plasmodium Falciparum
- Plasmodium Vivax
- Anopheles Species
- By Vaccine Type
- Pre-Erythrocytic
- Erythrocytic
- Multi-antigen
- By Distribution Channel
- Public
- Private
- By Country
- U.S.
- Canada
- By Agent
- Latin America
- By Agent
- Plasmodium Falciparum
- Plasmodium Vivax
- Anopheles Species
- By Vaccine Type
- Pre-Erythrocytic
- Erythrocytic
- Multi-antigen
- By Distribution Channel
- Public
- Private
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Agent
- Europe
- By Agent
- Plasmodium Falciparum
- Plasmodium Vivax
- Anopheles Species
- By Vaccine Type
- Pre-Erythrocytic
- Erythrocytic
- Multi-antigen
- By Distribution Channel
- Public
- Private
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Agent
- Asia Pacific
- By Agent
- Plasmodium Falciparum
- Plasmodium Vivax
- Anopheles Species
- By Vaccine Type
- Pre-Erythrocytic
- Erythrocytic
- Multi-antigen
- By Distribution Channel
- Public
- Private
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Agent
- Middle East
- By Agent
- Plasmodium Falciparum
- Plasmodium Vivax
- Anopheles Species
- By Vaccine Type
- Pre-Erythrocytic
- Erythrocytic
- Multi-antigen
- By Distribution Channel
- Public
- Private
- By Country
- GCC
- Israel
- Rest of Middle East
- By Agent
- Africa
- By Agent
- Plasmodium Falciparum
- Plasmodium Vivax
- Anopheles Species
- By Vaccine Type
- Pre-Erythrocytic
- Erythrocytic
- Multi-antigen
- By Distribution Channel
- Public
- Private
- By Country
- South Africa
- Central Africa
- North Africa
- By Agent
- North America